NCT06690775 2025-12-23
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
TORL Biotherapeutics, LLC
Phase 2 Recruiting
TORL Biotherapeutics, LLC
Sun Yat-sen University
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Institute of Oncology Ljubljana